Table 2.
Demographic data, baseline lipid abnormalities and secondary factors.
| Total patients (n = 301) | n (%) or mean ± SD (of whom information available) |
|
|---|---|---|
| Information available N (% of Total) | ||
| Age (years) | 269 (89.4) | 37.9 ± 10.4 |
| Sex | 263 (87.4) | |
| Male | 188 (71.5) | |
| Female | 74 (28.1) | |
| Race | 18 (6.0) | |
| Caucasian | 7 (38.9) | |
| Black | 3 (16.7) | |
| Hispanic | 5 (27.8) | |
| Asian | 3 (16.7) | |
| BMI (kg/m2) | 44 (14.6) | 26.6 ± 4.9 |
| Prior pancreatitis | 78 (25.9) | |
| Yes | 55 (70.5) | |
| No | 23 (29.5) | |
| Baseline lipid | 117 (38.9) | |
| abnormality (Fredrickson classification) |
||
| I | 1 (0.9) | |
| II | 7 (6.0) | |
| III | 2 (1.7) | |
| IV | 23 (19.7) | |
| V | 20 (17.1) | |
| Othera | 64 (54.7) | |
| Second factor | 149 (49.5) | |
| Diabetes | 75 (50.3) | |
| Alcohol | 57 (38.3) | |
| Pregnancy | 18 (12.1) | |
| Medication | 9 (6.0) | |
| Otherb | 3 (2.0) |
BMI: body mass index.
a
Other lipid abnormalities described by authors included “dyslipidemia” (n = 61), “familial HTG” (n = 1), type IV or V (n = 1), and peroxisome proliferator-activated receptor gamma genetic mutation (n = 1).
b
Authors listed coronary artery disease, amyloidosis, and uremia as contributing factors in one case each.